ABSTRACT: Background. The purpose of this study was to establish the efficacy and toxicities of concurrent erlotinib and docetaxel with intensity-modulated radiotherapy (IMRT) for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients received daily erlotinib for 2 weeks, followed by daily IMRT with concurrent weekly docetaxel and daily erlotinib, followed by daily erlotinib for up to 2 years. The primary objective was disease-free survival (DFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities. Forty-three patients were recruited for this study. Results. With a median follow-up of 48.7 months, the 3-year DFS, OS, locoregional failure-free survival, and distant metastasis-free survival was 69.5%, 81%, 82.4%, and 83.7%, respectively. The most common grade III/IV local toxicities were dysphagia, dermatitis, and mucositis. Patients with p16-positive tumors had significantly better outcomes. Conclusion. The regimen is tolerable and effective. It is worthy of further investigation in selected patients and may be useful in patients who cannot tolerate cisplatin.
INTRODUCTION
Head and neck cancer is the eighth most common cancer in the United States. 1 For locally advanced head and neck squamous cell carcinoma (HNSCC), concurrent chemoradiotherapy (CRT) has been established as the standard treatment with multiple randomized trials and meta-analyses. [2] [3] [4] [5] [6] However, despite incremental improvements in locoregional control and survival, a significant number of patients have persistent or recurrent disease. The combination of new agents with radiotherapy is of great interest to further improve treatment outcomes.
Most HNSCCs have overexpression of epidermal growth factor receptor (EGFR), which plays an important role in several cellular processes associated with malignancy. Targeting EGFR has gained importance in recent years. Cetuximab, a chimeric antibody against EGFR, has been shown to improve survival when given concurrently with radiation in HNSCC. 7, 8 However, cetuximab is expensive, requires weekly intravenous administration, and carries a risk of allergic reaction. Erlotinib is an oral tyrosine kinase inhibitor of EGFR. A preclinical model has shown that erlotinib has a significant radiosensitizing effect. 9 Clinically, it has been approved for use in nonsmall cell lung cancer and advanced pancreatic cancer. It has also been shown to be effective in HNSCC. In a pilot study of neoadjuvant treatment in HNSCC, erlotinib was given to 35 patients for a median of 20 days before surgery and 29% patients had tumor shrinkage. 10 In a phase II trial of erlotinib and cisplatin in recurrent/metastatic HNSCC, a 21% response rate was noted with 1 complete response and 8 partial responses; 49% of the patients had stable disease. 11 Therefore, erlotinib merits further evaluation in the treatment of HNSCC.
Cisplatin is the most common chemotherapeutic agent given concurrently with radiation in HNSCC. However, many patients cannot tolerate cisplatin because of its toxicity. Furthermore, recent data have emerged that the addition of EGFR inhibitors to concurrent cisplatin CRT did not improve treatment outcomes, possibly because of the similar effects on DNA repair by these agents.
should be evaluated in combination with EGFR inhibitors and radiotherapy.
Docetaxel is a potent radiosensitizer and also has a favorable toxicity profile when compared to cisplatin. 16 Human tumor xenograft studies have indicated that cetuximab is more effective in combination with docetaxel and radiation than with cisplatin and radiation. 17 Our group has extensive experience in studying the efficacy and toxicity of targeted therapies added to a docetaxel-based CRT regimen both in phase I and phase II setting. [18] [19] [20] We have completed a phase I trial combining erlotinib, docetaxel, and concurrent radiation in HNSCC and found the regimen to be feasible and tolerated. 18 We are now reporting a phase II trial of this treatment regimen.
MATERIALS AND METHODS
This was a nonrandomized open label phase II study approved by the Institutional Review Boards of Case Comprehensive Cancer Center. All patients provided Institutional Review Board-approved written informed consent before study enrollment.
Patient eligibility and baseline assessment
Eligible patients had histologically confirmed previously untreated stage III to stage IVA/B HNSCC. Patients were evaluated by a multidisciplinary team that included otolaryngologists, medical oncologists, and radiation oncologists. Each case was presented at a multidisciplinary tumor board for treatment recommendation and eligibility for this clinical trial. Pretreatment evaluation included medical history, physical examination, triple endoscopy, and radiographic imaging of the neck and chest. All patients underwent dental evaluation before treatment. All patients were required to have an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate bone marrow, renal, and hepatic functions. Percutaneous gastrostomy (PEG) tubes were placed in the majority of patients before treatment.
Patients with squamous cell carcinoma of the salivary glands, paranasal sinuses, and nasopharynx were excluded from the study. Other exclusion criteria were grade 2 preexisting peripheral neuropathy, history of allergic reactions to the chemotherapeutic agents, uncontrolled intercurrent diseases, and positive human immunodeficiency virus status.
Protocol treatment
The treatment schema is summarized in Figure 1 .
Chemotherapy
The treatment was administered on an outpatient basis. Erlotinib 150 mg/day was administered orally or via PEG tube for 2 weeks before radiation, during radiation, and up to 2 years after completion of radiation. Adjuvant erlotinib was terminated if the patient refused, had significant toxicity, or had disease progression. Docetaxel was administered intravenously at the beginning of radiation and weekly during the course of radiation. A dose of 20 mg/m 2 was given over a 60-minute infusion. Premedication included dexamethasone 4 mg orally daily for 3 days starting 24 hours before docetaxel, and Benadryl 50 mg and ranitidine 50 mg intravenously 30 minutes before docetaxel. Antiemetic agents were also administered 30 minutes before docetaxel.
Radiotherapy
Radiotherapy was delivered concurrently with chemotherapy using standard once-daily fractionation 5 days a week. All patients were treated with intensity-modulated radiotherapy (IMRT). In general, 3 target volumes were defined. Clinical target volume (CTV)1 was the primary tumor and involved nodes with a margin that was treated to 70 Gy. CTV2 was the high-risk areas that may harbor microscopic disease, including soft tissue around CTV1 and the high-risk lymphatic regions. CTV2 was treated to 63 Gy. CTV3 was the intermediate-risk areas and was treated to 56 Gy. All these volumes were treated simultaneously using the dose painting technique in 35 daily fractions.
Study evaluation and assessment of response
The adverse events were evaluated weekly using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. CT scans of the neck and chest and optional fluorodeoxyglucose positron emission tomography scans were obtained 8 to 12 weeks after completion of concurrent CRT. Salvage surgery was performed for patients with persistent or recurrent disease. The patients were seen monthly if they remained on adjuvant erlotinib for up to 2 years, and every 3 months thereafter.
Study objectives and statistical considerations
The primary objective of this study was to determine the 3-year disease-free survival (DFS) of patients with locally advanced HNSCC treated with the combination of docetaxel, erlotinib, and concurrent radiotherapy. Secondary endpoints included locoregional control rate, duration of response, patterns of failure, and overall survival (OS). Based on phase II/III clinical trials of chemoradiation in the treatment of locally advanced HNSCC at the time the study was designed, it was estimated that the probability of DFS at 3 years after treatment was about 50%. To detect an improvement in the 3-year DFS rate from 50% to 70% with a significance level of 0.05 and 80% power, the study required 43 patients.
DFS, OS, distant metastasis-free survival, local failurefree survival, regional failure-free survival, and locoregional failure-free survival were estimated by KaplanMeier method and the difference of survival between groups was examined by log-rank test. All tests are 2-sided and p values .05 were considered statistically significant. All survivals were calculated from the start of treatment to the date of the event and censored at the date of last follow-up for those alive and without event.
RESULTS

Patient characteristics
From August 2005 through December 2011, 43 patients were enrolled on the study. Patient characteristics are summarized in Table 1 . The median age was 57 years (range, 35-75 years). The primary sites included 29 oropharynx, 11 larynx, and 3 oral cavity (2 oral tongue and 1 retromolar trigone). The majority of patients had stage IVA/B disease (81%). The primary T classification was split between T1/T2 (47%) and T3/T4 (53%). The majority of patients had N2 to N3 nodal disease (72%).
The human papillomavirus (HPV) status was determined retrospectively using p16 as a surrogate maker on 36 patients who had tissue available for further testing. Of these patients, 23 were HPV-positive, all with oropharyngeal cancer. Of the 13 patients with p16-negative tumors, 4 had oropharyngeal cancer. All 3 patients with oral cavity cancer were p16-negative and 6 of 11 patients with laryngeal cancer who were tested had p16-negative tumors.
Treatment delivery and toxicities
Of the 43 patients enrolled in the study, 41 completed the full course of radiotherapy, with a median of 52 days (range, 45-64 days). One patient refused to continue at 62 Gy because of the side effects. One patient died suddenly at 36 Gy of an unknown cause.
Thirty-seven of 43 patients received 6 or more infusions of docetaxel concurrently with radiation. One patient received 5 infusions, 4 patients received 4 infusions, and 1 patient received 3 infusions. Seven patients required a dose reduction to 15 mg/m 2 , mainly because of elevated liver enzymes.
During CRT, 31 patients received the full dosage of erlotinib with no dose reduction. Ten patients had 1 dose reduction to 100 mg daily because of skin rashes (5 patients), elevation of liver enzymes (3 patients), mucositis (1 patient), and hypertension (1 patient). Two patients had 2 dose reductions to 50 mg because of skin rashes (1 patient) and gastritis with nausea (1 patient). After CRT, 28 patients received adjuvant erlotinib for a median of 5 months. Five of them received more than 20 months of adjuvant erlotinib. The major reason for patients not completing adjuvant erlotinib was patient refusal (58%), followed by disease progression (24%), intercurrent diseases, and surgical procedures. Only 2 patients discontinued adjuvant erlotinib because of skin toxicity.
Selected acute toxicities of the treatments are shown in Table 2 . The most common hematologic grade III or higher toxicity was lymphopenia (95%). The most common nonhematologic grade III or higher toxicities were dysphagia (49%), dermatitis (37%), and mucositis (35%). There was 9% of grade III acneiform skin rashes. Grade III late toxicities included mandibular osteoradionecrosis (2 patients; 1 because of dental extraction), dysphagia (4 patients), and laryngeal cartilage necrosis (1 patient who continued to smoke after treatment). A prophylactic PEG tube was placed routinely. Most patients had their tube removed 1 to 3 months after radiation treatment. Two patients remained PEG tube dependent for more than 1 year after radiation.
Survival and patterns of failure
The median follow-up was 48.7 months (range, 1.4-82.1 months). The 3-year DFS, OS, local failure-free survival, regional failure-free survival, locoregional failure-free survival, and distant metastasis-free survival was 69.5%, 81%, 90%, 87.1%, 82.4%, and 83.7%, respectively (see Figure  2) . Twenty-eight patients received adjuvant erlotinib after CRT. There was no significant difference in any outcome in these patients compared to those who did not receive adjuvant therapy (data not shown).
Patients with a p16-positive tumor had significantly better DFS, OS, regional failure-free survival, and locoregional failure-free survival than those with a p16-negative tumor ( Table 3) . The difference in local failure-free survival was borderline significant, 95.7% for p16-positive patients versus 72.9% for p16-negative patients (p 5 .06). There was no significant difference in 3-year distant metastasis-free survival between those who were p16-positive versus those who were p16-negative, with a trend favoring p16-positive patients (86.4% vs 71.4%; p 5 .608).
Of 29 patients with oropharyngeal cancer, 1 patient had local failure, 2 patients had regional failure, and 4 patients had distant failure as the only site of failure. At last followup, 7 patients had died, 4 from distant disease, 1 from locoregional disease, and 2 from other causes. Of 11 patients with laryngeal cancer, 1 had local failure, 1 had both local and regional recurrence, and 1 patient had distant failure only. At last follow-up, 8 patients were alive and 7 of them were able to retain their larynx. Of the 3 patients with oral cavity cancer, 1 1 patient died at 32 Gy of unknown reasons, 1 patient had persistent unsalvageable disease after treatment, and 1 patient developed regional recurrence and later died of lung metastases.
DISCUSSION
We are reporting here a nonrandomized open label phase II clinical trial using a novel combination of concurrent erlotinib, docetaxel, and radiation in the management of locally advanced HNSCC. There are 3 other phase II studies that have been published recently combining erlotinib and other chemotherapeutic agent(s) with radiation in HNSCC. They are summarized in Table 4 . [21] [22] [23] Hainsworth et al 21 combined bevacizumab, erlotinib, paclitaxel, and radiation. In their nonrandomized phase II trial, patients were treated with 2 cycles of neoadjuvant chemotherapy with bevacizumab, carboplatin, paclitaxel, and 5-fluoruracil before concurrent CRT. Yoo et al 22 combined bevacizumab, erlotinib, cisplatin, and radiation. Radiation was delivered twice daily at 1.25 Gy per fraction with a 6-hour interfraction interval and a planned 1-week break during week 4. Martins et al 23 reported a randomized phase II trial comparing cisplatin and radiotherapy with or without erlotinib. All these studies showed that the addition of erlotinib to CRT in HNSCC was feasible and tolerable. The treatment outcomes were comparable to those treated with standard CRT regimens in recent clinical trials, such as Radiotherapy Oncology Group (RTOG) 0129 and RTOG 0522 (Table 4) . RTOG 0129 24 was a phase III randomized trial comparing concurrent cisplatin with an accelerated concomitant boost versus standard fractionation radiation in locally advanced HNSCC. From July 2002 to May 2005, 743 cases were entered. There were no differences observed between the 2 arms in 5-year OS (59% vs 56%; p 5 .18), 5-year DFS (45% vs 44%; p 5 .42), 5-year locoregional failure (31% vs 28%; p 5 .76), or 5-year distant metastasis (18% vs 22%; p 5 .06). RTOG 0522 12 was a randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for locally advanced HNSCC. In the analysis of 891 patients entered in the trial at a median follow-up of 3.8 years, the 3-year DFS was 61.2% versus 58.9% (p 5 .76), and the 3-year OS was 72.9% versus 75.8% (p 5 .32) in the patients treated without or with cetuximab, respectively.
Of note, in a randomized phase II study, Martins et al 23 showed that erlotinib did not improve the complete response rate and DFS in patients with locally advanced HNSCC when added to cisplatin-radiotherapy. However, cisplatin might not be the most optimal cytotoxic radiosensitizing agent when EGFR inhibitor is added to concurrent CRT. In addition to the RTOG 0522 trial mentioned above, Eriksen et al 14 recently reported a Danish randomized study (DAHANCA 19) showing that the addition of zalutumumab, a monoclonal antibody to EGFR receptor, to cisplatin-radiotherapy and nimorazole did not increase the locoregional control, DFS, or OS at 3 years. Mesia et al 15 also reported that the addition of panitumumab, a fully human monoclonal antibody targeting EGFR, to standard fractionation radiotherapy and cisplatin did not confer any benefit in patients with locally advanced HNSCC. Therefore, chemotherapeutic agents other than cisplatin should be evaluated when an EGFR inhibitor is added to the CRT regimen.
RTOG 0234 was a phase II randomized clinical trial evaluating postoperative radiation plus concurrent docetaxel and cetuximab versus postoperative radiation plus cisplatin and cetuximab for high-risk HNSCC after surgery. The results showed an impressive improvement in 2-year OS and DFS of the docetaxel arm compared to the cisplatin arm (79% vs 69%, and 66% vs 57%, respectively). 13 When compared to the historical controls of patients treated with cisplatin and radiation from RTOG 9501, there was an absolute improvement in 2-year DFS of 11.1% and 2.5%, respectively. Although the benefit of the docetaxel arm seemed to be related to the better control of distant disease, these results led to a phase III randomized RTOG trial, RTOG 1216, which compares postoperative radiation with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk patients with HNSCC. 25 Our study is the first evaluating the combination of erlotinib and docetaxel administered concurrently with radiotherapy. Erlotinib is a small molecule tyrosine kinase inhibitor of EGFR administrated orally. This is more convenient to patients, and it does not have the same allergic reaction potential as cetuximab.
Our results showed that such a regimen is feasible. The major local side effects noted in our trial were dysphagia, mucositis, and dermatitis. These are consistent with other reports as well as those reported in clinical trials using standard concurrent CRT in HNSCC. [2] [3] [4] 12, 13, 24 This suggests that erlotinib did not increase the acute local toxicities of CRT. The grade III dysphagia in our trial might be over rated because of our routine PEG tube placement. Our patients likely use their tube feeding earlier in the treatment course, which is graded as grade 3 toxicity in National Cancer Institute Common Terminology Criteria for Adverse Events. Most patients had their PEG tube removed 1 to 3 months after treatment except for 2 patients who kept the tube for more than 1 year.
The decision to include adjuvant erlotinib was based upon preclinical data by Milas et al 26 showing that the addition of a few doses of cetuximab after radiation plus concurrent cetuximab improved the curative effect of the treatment. In the EXTREME trial, 27 in which patients were randomized to chemotherapy alone or chemotherapy plus cetuximab, chemotherapy was given for up to 6 cycles, but cetuximab was continued beyond chemotherapy until disease progression or unacceptable toxicity. In this trial, the addition of adjuvant erlotinib did not provide any benefit in treatment outcomes. Many patients refused to continue the medication because of the inconvenience of monthly follow-up and laboratory tests to monitor the side effects. Therefore, in future clinical trials if adjuvant targeted therapy is considered, it may be better to limit the treatment duration to 1 to 3 months after CRT to improve compliance. This trial also provides valuable data regarding the optimal weekly dosage of docetaxel given concurrently with radiation. In our study, docetaxel administered at a weekly dose of 20 mg/m 2 during concurrent radiation treatment was well-tolerated. Our group has also completed a phase II study combining radiation, docetaxel, and bevacizumab and has demonstrated that docetaxel at 20 mg/m 2 /week was well-tolerated in combination with bevacizumab and radiation. 20 It is of interest to note that a lower docetaxel dose (15 mg/m 2 /week) was selected in the phase III RTOG 1216 clinical trial. 25 Recently, there has been a significant increase in the incidence of HPV-related oropharyngeal cancer. 28 This represents a separate entity of head and neck cancer with a very good response to treatment, and a significantly better prognosis as compared to HPV-negative cancer. 29 Our limited data in oropharyngeal cancer have confirmed these findings. Currently, clinical trials looking at treatment deintensification are underway for HPV-related oropharyngeal cancer. 30 However, all 3 patients with oral cavity cancer recruited in this trial have died of disease progression. These patients probably should have had surgery first followed by adjuvant CRT based on the pathology features rather than being treated with definitive CRT. For laryngeal cancer, this regimen may be promising. We recruited 11 patients with laryngeal cancer in the trial, all with locally advanced disease (8 with classification T3 and 3 with T4A disease). There were only 2 local failures that required salvage laryngectomy. At last follow-up, 8 patients were alive and 7 of them kept their larynx. This regimen may be worthy of further investigation in laryngeal cancer. It may also be useful as an alternative in patients who cannot tolerate cisplatin-based CRT.
CONCLUSION
We are reporting the results of our phase II trial looking at the combination of erlotinib and docetaxel given concurrently with IMRT in locally advanced HNSCC. The treatment regimen is feasible with an expected side effect profile that is similar to standard CRT. Patients with p16-positive oropharyngeal cancer had a very good response to the treatment with 96% locoregional control. This treatment regimen showed promising treatment outcomes in a small number of patients with laryngeal cancer, and may be worthy of further evaluation for laryngeal preservation. This combination may also be useful as an alternative for patients who cannot tolerate cisplatin-based CRT.
